Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk

Area of Science:

• Neurology
• Cardiology
• Clinical Trials

Background:

• Current guidelines suggest initiating anticoagulation 4-14 days post-cardioembolic stroke.
• Previous data did not fully consider factors like infarct size or hemorrhagic transformation.
• Optimal timing for anticoagulation initiation remains unclear.

Purpose of the Study:

• To evaluate the association between the timing of anticoagulation initiation and outcomes in patients with ischemic stroke and atrial fibrillation.
• To investigate if the recommended 4-14 day window reduces recurrent ischemic events or bleeding complications.

Main Methods:

• Pooled data from 8 US stroke registries.
• Included consecutive patients with ischemic stroke and atrial fibrillation.
• Analyzed outcomes (recurrent stroke, systemic embolism, symptomatic intracerebral hemorrhage, extracranial hemorrhage) based on anticoagulation initiation at 0-3 days, 4-14 days, or >14 days.

Main Results:

• 1,289 patients were analyzed; 10.1% experienced a combined endpoint event.
• No significant difference in composite endpoints was observed between the three initiation time groups (p=0.933).
• Initiating anticoagulation between 4-14 days did not reduce symptomatic intracerebral hemorrhage or recurrent ischemic events compared to other groups.

Conclusions:

• The recommended 4-14 day window for initiating oral anticoagulation post-stroke was not associated with improved ischemic or hemorrhagic outcomes in this real-world cohort.
• Randomized controlled trials are necessary to establish the optimal timing for anticoagulation initiation.
• Findings challenge current guideline recommendations for anticoagulation timing in cardioembolic stroke.